Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Relistor

This page shows the latest Relistor news and features for those working in and with pharma, biotech and healthcare.

Valeant's proposed sale of Salix to Takeda 'in jeopardy'

Valeant's proposed sale of Salix to Takeda 'in jeopardy'

Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands. ... Xifaxan and Relistor are integral to our gastrointestinal franchise which remains a core asset for future growth potential in the hands of Valeant.".

Latest news

  • Valeant swoops on Salix with $10bn takeover deal Valeant swoops on Salix with $10bn takeover deal

    Valeant and Salix are also expecting to benefit from the launch of a new oral form of its injectable Relistor (methylnaltrexone bromide) product for cancer pain.

  • Valeant and Shire said to be evaluating potential Salix bids Valeant and Shire said to be evaluating potential Salix bids

    Nevertheless, in the latter half of last year Salix introduced three new products - Ruconest for hereditary angioedema, Relistor (methylnaltrexone bromide) subcutaneous injection for chronic non-cancer pain and Uceris (budesonide) rectal

  • AstraZeneca has clearer route to Movantik approval in US AstraZeneca has clearer route to Movantik approval in US

    Concern about the safety of the PAMORA class - which also includes Cubist Pharma's Entereg (alvimopan) and Salix' Relistor (methylnaltrexone) - emerged after one of phase III trials conducted with Entereg showed

  • Salix boosts GI portfolio with $2.6bn deal for Santarus Salix boosts GI portfolio with $2.6bn deal for Santarus

    Salix also brings a number of smaller GI products including Apriso (mesalamine) for ulcerative colitis (UC) and Relistor (methylnaltrexone bromide) for opioid-induced constipation, while Santarus provides recently-launched Uceris (budesonide)

  • Creative partnerships

    Platform. 614. Xencor/Amgen. XmAb5871, mAb for auto-immune diseases. Preclinical. 500. Allergan/Valeant (Biovail) ###. Aczone for acne vulgaris. Marketed. 450. Progenics/Salix. Relistor for opioid induced constipation.

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals in February 2015 Pharma deals in February 2015

    On the other hand, Salix boasts a 22 product portfolio including the prescription brands Uceris (ulcerative colitis), Relistor (constipation), and Apriso (ulcerative colitis) and a strong near-term pipeline, however the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...

Quick links